Multicentre, Single-arm, Non-interventional Regulatory Post- Marketing Surveillance (rPMS) Study to Evaluate the Safety and Effectiveness of Saxenda for Weight Management in Routine Clinical Practice in Taiwan
Latest Information Update: 11 Apr 2025
At a glance
- Drugs Liraglutide (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 27 Mar 2025 Status changed from active, no longer recruiting to completed.
- 12 Dec 2024 Status changed from recruiting to active, no longer recruiting.
- 01 Apr 2024 Status changed from not yet recruiting to recruiting.